北大医药：2025年全年净利润同比预减33.33%—47.82%

Core Viewpoint - The company, Peking University Pharmaceutical, is forecasting a significant decline in net profit for the year 2025, with expectations of a decrease between 33.33% and 47.82% compared to the previous year [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between 72 million and 92 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 95 million and 115 million yuan, reflecting a year-on-year decrease of 9.64% to 25.35% [1] Reasons for Performance Decline - The decline in operating performance is primarily attributed to two factors: 1. The termination of business cooperation between the company's wholly-owned subsidiary, Beijing New Advantage Pharmaceutical Commercial Co., Ltd., and Peking University International Hospital, effective May 2025, which is expected to lead to a decrease in revenue and net profit [1] 2. The impact of expenses related to the disposal of personnel due to judicial arbitration in the pharmaceutical manufacturing sector, which is anticipated to reduce the total profit for the reporting period by 39 million to 45 million yuan [1]